Advanced search
Publication Cover
Expert Review of Hematology Volume 8, 2015 - Issue 4
Submit an article Journal homepage
2,050
Views
6
CrossRef citations to date
0
Altmetric
Editorial

Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?

Massimo BrecciaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, ItalyCorrespondence[email protected]
,
Matteo MolicaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Gioia ColafigliDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
&
Giuliana AlimenaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
Pages 387-389 | Published online: 27 Apr 2015

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Haifa Kathrin Al-Ali, Viktoriya Stalbovskaya, Prashanth Gopalakrishna, Julian Perez-Ronco & Lynda Foltz. (2016) Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. Leukemia & Lymphoma 57:10, pages 2464-2467.
Read now
J. M. O’Sullivan, D. P. McLornan & C. N. Harrison. (2016) Safety considerations when treating myelofibrosis. Expert Opinion on Drug Safety 15:9, pages 1185-1192.
Read now
Giovanni Caocci, Antonio Maccioni, Francesca Murgia, Alessandra Perra, Monica Usai, Michela Piga, Roberto Mascia & Giorgio La Nasa. (2016) Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis. Leukemia & Lymphoma 57:5, pages 1215-1218.
Read now

Articles from other publishers (3)

Eugenio Piro, Maria Lentini, Luciano Levato, Antonio Russo & Stefano Molica. (2018) Sustained Erythroid Response in a Patient with Myelofibrosis Receiving Concomitant Treatment with Ruxolitinib and Deferasirox. Chemotherapy 63:2, pages 107-110.
Crossref
Jennifer M. O'Sullivan & Claire N. Harrison. (2017) JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms. Molecular and Cellular Endocrinology 451, pages 71-79.
Crossref
G Barosi & R P Gale. (2016) How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?. Leukemia 30:7, pages 1453-1455.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.